How to buy Inovio Pharmaceuticals shares | $17.69
Own Inovio Pharmaceuticals shares in just a few minutes.
Inovio Pharmaceuticals, Inc is a biotechnology business with stocks listed in the US. Inovio Pharmaceuticals shares (INO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$17.69 – an increase of 29.79% over the previous week.
How to buy shares in Inovio Pharmaceuticals
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Inovio Pharmaceuticals. Find the share by name or ticker symbol: INO. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Inovio Pharmaceuticals reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$17.69, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Inovio Pharmaceuticals, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Inovio Pharmaceuticals. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
- Inovio Pharmaceuticals key stats
- Compare share trading platforms
- Is Inovio Pharmaceuticals stock a buy or sell?
- Inovio Pharmaceuticals performance over time
- Can I short Inovio Pharmaceuticals shares?
- Inovio Pharmaceuticals's financials
- How volatile are Inovio Pharmaceuticals shares?
- Does Inovio Pharmaceuticals pay a dividend?
- Have Inovio Pharmaceuticals shares ever split?
- Other common questions
How has coronavirus impacted Inovio Pharmaceuticals's share price?
Since the stock market crash in March caused by coronavirus, Inovio Pharmaceuticals's share price has had significant positive movement.
Its last market close was US$17.69, which is 78.83% up on its pre-crash value of US$3.745 and 463.38% up on the lowest point reached during the March crash when the shares fell as low as US$3.14.
If you had bought US$1,000 worth of Inovio Pharmaceuticals shares at the start of February 2020, those shares would have been worth US$1,693.07 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth US$4,524.22.
Inovio Pharmaceuticals share priceUse our graph to track the performance of INO stocks over time.
Inovio Pharmaceuticals shares at a glance
|Latest market close||USD$17.69|
|52-week range||USD$1.96 - USD$33.79|
|50-day moving average||USD$14.2144|
|200-day moving average||USD$14.3568|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.215|
Standard brokerage - US shares
Get $0 brokerage on US stocks with trades as little as $50 when you join the world’s biggest social trading network.
- $0 brokerage for US stocks
- Trades starting from $50
- Fractional shares
- Copy top traders
Important: Share trading carries risk of capital loss.
Compare share trading platforms
Is it a good time to buy Inovio Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Inovio Pharmaceuticals price performance over time
|1 week (2020-09-14)||56.27%|
|1 month (2020-08-21)||25.46%|
|3 months (2020-06-19)||23.97%|
|6 months (2020-03-20)||145.01%|
|1 year (2019-09-20)||613.31%|
|2 years (2018-09-21)||274.00%|
|3 years (2017-09-21)||181.24%|
|5 years (2015-09-21)||142.66%|
Inovio Pharmaceuticals financials
|Revenue TTM||US$2.7 million|
|Gross profit TTM||US$-82,005,389|
|Return on assets TTM||-22.79%|
|Return on equity TTM||-184.48%|
|Market capitalisation||US$2.8 billion|
TTM: trailing 12 months
Shorting Inovio Pharmaceuticals shares
There are currently 30.9 million Inovio Pharmaceuticals shares held short by investors – that's known as Inovio Pharmaceuticals's "short interest". This figure is 20% up from 25.8 million last month.
There are a few different ways that this level of interest in shorting Inovio Pharmaceuticals shares can be evaluated.
Inovio Pharmaceuticals's "short interest ratio" (SIR)
Inovio Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Inovio Pharmaceuticals shares currently shorted divided by the average quantity of Inovio Pharmaceuticals shares traded daily (recently around 9.4 million). Inovio Pharmaceuticals's SIR currently stands at 3.3. In other words for every 100,000 Inovio Pharmaceuticals shares traded daily on the market, roughly 3300 shares are currently held short.
However Inovio Pharmaceuticals's short interest can also be evaluated against the total number of Inovio Pharmaceuticals shares, or, against the total number of tradable Inovio Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Inovio Pharmaceuticals's short interest could be expressed as 0.31% of the outstanding shares (for every 100,000 Inovio Pharmaceuticals shares in existence, roughly 310 shares are currently held short) or 0.3158% of the tradable shares (for every 100,000 tradable Inovio Pharmaceuticals shares, roughly 316 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Inovio Pharmaceuticals.
Find out more about how you can short Inovio Pharmaceuticals stock.
Inovio Pharmaceuticals share dividends
We're not expecting Inovio Pharmaceuticals to pay a dividend over the next 12 months.
Have Inovio Pharmaceuticals's shares ever split?
Inovio Pharmaceuticals's shares were split on a 1:4 basis on 5 June 2014. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Inovio Pharmaceuticals shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Inovio Pharmaceuticals shares which in turn could have impacted Inovio Pharmaceuticals's share price.
Inovio Pharmaceuticals share price volatility
Over the last 12 months, Inovio Pharmaceuticals's shares have ranged in value from as little as US$1.96 up to US$33.79. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Inovio Pharmaceuticals's is 1.0903. This would suggest that Inovio Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Inovio Pharmaceuticals overview
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells and facilitate cross-strain protection against unmatched and matched pathogens. The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and collaborators include ApolloBio Corp., AstraZeneca PLC or AstraZeneca, Beijing Advaccine Biotechnology Co., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency's Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Roche/Genentech, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company also has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800, which is currently in Phase I clinical testing for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Frequently asked questions
Ask an Expert